Coma - 553 Studies Found
| Recruiting |
: Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma : Sarcoma, Alveolar Soft Part : 2009-07-18 : Drug: AZD2171 Cediranib (AZD2171), a VEGF/KIT tyrosine kinase inhibitor, has demonstrated antitumor acti |
| Completed |
: A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas :
|
| Completed |
: Phase 2 Study in Patients With MiT Tumors :
|
| Active, not recruiting |
: Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma :
|
| Not yet recruiting |
: Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma :
: |
| Recruiting |
: CREATE: Cross-tumoral Phase 2 With Crizotinib :
|
| Recruiting |
: Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery :
|
| Recruiting |
: Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma :
: |
| Completed |
: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma :
: |
| Completed |
: Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma :
: Drug: romidepsin DEP is administered at a dose of 13 mg/m2 as a 4-hour intravenous infusion in the outpa |